BUSINESS

Otsuka Paid 20 Billion Yen to Healthcare Professionals in FY2012, 5.4 Billion Yen for Information Provisioning

September 4, 2013
Otsuka Pharmaceutical paid 19,959 million yen to medical institutions and doctors in FY2012, the company revealed on September 2 under the transparency guidelines of the Japan Pharmaceutical Manufacturers Association. Of the total, 27% or 5,367 million yen was spent for…

To read the full story

BUSINESS

By Takashi Ebisawa

Generic drug makers are hailing the planned creation of a new government fund designed to support the industry’s manufacturing infrastructure,…

By Philip Carrigan

As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…

By Takashi Ebisawa

A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

By Ken Yoshino

Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…

For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…

A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…

A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

By Yoshinori Sagehashi

The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…